Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $5.9 million as the latest value for Q3 2023.

  • Quarterly Preferred Stock Liabilities changed N/A to $5.9 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Sep 2023, changed N/A year-over-year, with the annual reading at $5.9 million for FY2022, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q3 2023 was $5.9 million at LENZ Therapeutics, roughly flat from $5.9 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $44.6 million in Q1 2023, with the low at $5.9 million in Q4 2022.